3,4-二氢-2H-4-苯并噁嗪-2-羧酰胺 | 13582-93-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3,4-二氢-2H-4-苯并噁嗪-2-羧酰胺
• 英文名称: 3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxamide
• 英文别名: 3,4-Dihydro-2H-1,4-benzoxazine-2-carboxamide
• CAS: 13582-93-9
• 化学式: C₉H₁₀N₂O₂
• mdl: MFCD01663851
• 分子量: 178.191
• InChiKey: HFMCIPVAQHTOPB-UHFFFAOYSA-N

物化性质

• 熔点：
  145-148 °C
• 沸点：
  444.3±45.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-4-苯并噁嗪-2-羧酰胺 在 硫酸 、 锌 、 sodium nitrite 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 生成 4-benzylideneamino-3,4-dihydro-2H-benzo[1,4]oxazine-2-carboxylic acid amide
  参考文献：
  名称：

  Predvoditeleva,G.S.; Shchukina,M.N., Journal of Organic Chemistry USSR (English Translation), 1965, vol. 1, p. 1343 - 1344

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二氢-2H-苯并[1,4]噁嗪-2-羧酸乙酯 在 氨 作用下， 以 乙醇 为溶剂， 反应 14.0h， 生成 3,4-二氢-2H-4-苯并噁嗪-2-羧酰胺
  参考文献：
  名称：

  2-（2-咪唑啉基）取代的2,3-二氢-4 H -1,4-苯并噻嗪和3,4-二氢-2 H -1,4-苯并恶嗪的合成

  摘要：

  已经进行了2-（2-咪唑啉基）-1，4-苯并二恶烷的苯并恶嗪，苯并噻吨和苯并噻嗪衍生物的合成的研究。

  DOI：

  10.1002/jhet.5570220143

文献信息

• [EN] SUBSTITUTED 4-BENZYL-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-2CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1<br/>[FR] ANALOGUES SUBSTITUÉS DU 4-BENZYL-3,4-DIHYDRO-2H-BENZO[B] [1,4] OXAZINE-2-CARBOXAMIDE, UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR MUSCARINIQUE DE L'ACÉTYLCHOLINE M1
  申请人：UNIV VANDERBILT

  公开号：WO2015080904A1

  公开（公告）日：2015-06-04

  In one aspect, the invention relates to N-substituted 3,4-dihydro-benzo[£][l,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，这项发明涉及N-取代的3,4-二氢苯并[£][1,4]噁嗪-2-羧酰胺类似物，其衍生物和相关化合物，这些化合物可用作肌胆碱受体M1（mAChR M1）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与肌胆碱受体功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域搜索的扫描工具，并不意味着对本发明的限制。
• Fused Quinoline Derivative and Use Thereof
  申请人：Kajino Masahiro

  公开号：US20080039452A1

  公开（公告）日：2008-02-14

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R 1 is a hydrogen atom and the like; R 2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R 3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R 4 and R 5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R 6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R 7 , R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, halogen and the like; or R 7 and R 8 , R 8 and R 9 , and R 9 and R 10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，涉及一种由式（I）表示的化合物，其中R1为氢原子等；R2为氢原子、烃基可选地具有取代基等；R3为未取代（即不存在）、氢原子等；R4和R5相同或不同，每个都是氢原子、烃基可选地具有取代基等；R6为（环状基团可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个都是氢原子、卤素等；或R7和R8、R8和R9以及R9和R10可以与相邻的碳原子一起形成环；n为1到5的整数；---表示未取代（即不存在）或单键；表示单键或双键，或其盐等。
• FUSED QUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Kajino Masahiro

  公开号：US20090258893A1

  公开（公告）日：2009-10-15

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R 1 is a hydrogen atom and the like; R 2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R 3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R 4 and R 5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R 6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R 7 , R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, halogen and the like; or R 7 and R 8 , R 8 and R 9 , and R 9 and R 10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子、烃基（可选取取代基等）等；R3是未取代（即不存在）、氢原子等；R4和R5相同或不同，且每个都是氢原子、烃基（可选取取代基等）等；R6是（环状基团可选取取代基等）-羰基等；R7、R8、R9和R10相同或不同，且每个都是氢原子、卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；表示未取代（即不存在）或单键；和表示单键或双键，或其盐等。
• Fused quinoline derivative and use thereof
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2080760A1

  公开（公告）日：2009-07-22

  Use of a compound represented by the formula (I) wherein R1 is (1) unsubstituted, (2) a hydrogen atom, (3) a hydrocarbon group optionally having substituent(s) or (4) acyl; R2 is (1) a hydrogen atom, (2) a hydrocarbon group optionally having substituent(s), (3) hydroxy optionally having a substituent, (4) amino optionally having substituent(s), (5) thiol optionally having a substituent, (6) a heterocyclic group optionally having substituent(s) or (7) acyl; R3 is (1) unsubstituted, (2) a hydrogen atom, (3) a hydrocarbon group optionally having substituent(s), (4) hydroxy optionally having a substituent, (5) amino optionally havingsubstituent(s), (6) thiol optionally having a substituent or (7) acyl; R4 and R5 are the same or different and each is (1) a hydrogen atom, (2) a hydrocarbon group optionally having substituent (s), (3) hydroxyoptionallyhavingasubstituent, (4) amino optionally having substituent (s), (5) thiol optionally having a substituent or (6) acyl; R6 is (1) (cyclic group optionally having substituent(s))-carbonyl, (2) alkenylcarbonyl optionally having substituent (s), (3) alkylcarbonyl having substituent (s) selected from (i) cycloalkyl optionally having substituent (s), (ii) amino optionally having substituent(s) and (iii) a heterocyclic group optionally having substituent(s) or (4) a heterocyclic group optionally having substituent(s); R7, R8, R9 and R10 are the same or different and each is (1) a hydrogen atom, (2) halogen, (3) cyano, (4) nitro, (5) a hydrocarbon group optionally having substituent(s), (6) hydroxy optionally having a substituent, (7) amino optionally having substituent(s), (8) thiol optionally having a substituent, (9) a heterocyclic group optionally having substituent(s) or (10) acyl; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted or a single bond; and; --- represents a single bond or a double bond, or a salt thereof, for the production of an agent for the prophylaxis or treatment of melancholia.

  使用式 (I) 所代表的化合物 其中 R1 是(1)未取代的氢原子，(2)氢原子，(3)任选具有取代基的烃基或(4)酰基； R2 是(1)氢原子，(2)任选具有取代基的烃基，(3)任选具有取代基的羟基，(4)任选具有取代基的氨基，(5)任选具有取代基的硫醇，(6)任选具有取代基的杂环基团或(7)酰基； R3 是(1)未取代的，(2)氢原子，(3)任选具有取代基的烃基，(4)任选具有取代基的羟基，(5)任选具有取代基的氨基，(6)任选具有取代基的硫醇或(7)酰基； R4 和 R5 相同或不同，各自是 (1) 氢原子，(2) 可选择具有取代基的烃基，(3) 可选择具有取代基的羟基，(4) 可选择具有取代基的氨基，(5) 可选择具有取代基的硫醇或 (6) 丙烯酸； R6 是(1)（任选具有取代基的环基）-羰基，(2)任选具有取代基的烯基羰基，(3)任选具有取代基的烷基羰基，这些取代基选自(i)任选具有取代基的环烷基，(ii)任选具有取代基的氨基和(iii)任选具有取代基的杂环基团或(4)任选具有取代基的杂环基团； R7、R8、R9 和 R10 相同或不同，且各自为：(1) 氢原子，(2) 卤素，(3) 氰基，(4) 硝基，(5) 任选具有取代基的烃基，(6) 任选具有取代基的羟基，(7) 任选具有取代基的氨基，(8) 任选具有取代基的硫醇，(9) 任选具有取代基的杂环基团或 (10) 丙烯酸基；或 R7 和 R8、R8 和 R9 以及 R9 和 R10 可与相邻的碳原子一起形成一个环； n 是 1 至 5 的整数； ----代表未取代或单键；以及 ----代表单键或双键，或其盐，用于生产预防或治疗忧郁症的制剂。
• Discovery of Dihydro-1,4-Benzoxazine Carboxamides as Potent and Highly Selective Inhibitors of Sirtuin-1
  作者：Martin Spinck、Matthias Bischoff、Philipp Lampe、Franz-Josef Meyer-Almes、Sonja Sievers、Heinz Neumann

  DOI：10.1021/acs.jmedchem.1c00017

  日期：2021.5.13